DK2932264T3 - Nye MHC-uafhængige tumor-associerede antigener - Google Patents

Nye MHC-uafhængige tumor-associerede antigener Download PDF

Info

Publication number
DK2932264T3
DK2932264T3 DK13818713.3T DK13818713T DK2932264T3 DK 2932264 T3 DK2932264 T3 DK 2932264T3 DK 13818713 T DK13818713 T DK 13818713T DK 2932264 T3 DK2932264 T3 DK 2932264T3
Authority
DK
Denmark
Prior art keywords
associated antigens
independent tumor
novel mhc
mhc
novel
Prior art date
Application number
DK13818713.3T
Other languages
English (en)
Inventor
Dirk Schadendorf
Martina Fatho
Hakim Echchannaoui
Volker Lennerz
Catherine Wölfel
Thomas Wölfel
Anette Paschen
Silke Lübcke
Daniela Eberts
Original Assignee
Biontech Rna Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech Rna Pharmaceuticals Gmbh filed Critical Biontech Rna Pharmaceuticals Gmbh
Application granted granted Critical
Publication of DK2932264T3 publication Critical patent/DK2932264T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A61K39/001118—Receptors for colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7153—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for colony-stimulating factors [CSF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y503/00—Intramolecular oxidoreductases (5.3)
    • C12Y503/03—Intramolecular oxidoreductases (5.3) transposing C=C bonds (5.3.3)
    • C12Y503/03012—L-Dopachrome isomerase (5.3.3.12)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
DK13818713.3T 2012-12-14 2013-12-16 Nye MHC-uafhængige tumor-associerede antigener DK2932264T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12197289 2012-12-14
PCT/EP2013/076760 WO2014091034A1 (en) 2012-12-14 2013-12-16 Novel mhc-independent tumor-associated antigens

Publications (1)

Publication Number Publication Date
DK2932264T3 true DK2932264T3 (da) 2019-05-06

Family

ID=47355928

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13818713.3T DK2932264T3 (da) 2012-12-14 2013-12-16 Nye MHC-uafhængige tumor-associerede antigener

Country Status (13)

Country Link
US (2) US9861688B2 (da)
EP (1) EP2932264B1 (da)
JP (1) JP6475166B2 (da)
AU (2) AU2013357239B2 (da)
CA (2) CA3108192A1 (da)
DK (1) DK2932264T3 (da)
ES (1) ES2721159T3 (da)
HU (1) HUE042967T2 (da)
PL (1) PL2932264T3 (da)
PT (1) PT2932264T (da)
SI (1) SI2932264T1 (da)
TR (1) TR201905447T4 (da)
WO (1) WO2014091034A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA034110B1 (ru) * 2013-03-15 2019-12-27 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Противораковые вакцины и способы лечения с их применением
US10414812B2 (en) * 2015-02-16 2019-09-17 The Trustees Of The University Of Pennsylvania Fully-human T-cell receptor specific for the 369-377 epitope derived from the Her2/neu (ERBB2) receptor protein
CN111886243A (zh) 2018-02-11 2020-11-03 纪念斯隆-凯特琳癌症中心 非-hla限制性t细胞受体及其用途
WO2022093333A1 (en) * 2020-10-27 2022-05-05 T-Cure Biosciences, Inc. Recombinant t-cell receptors that bind the ny-eso-1 and/or lage-1a cancer antigens
WO2022155375A2 (en) * 2021-01-13 2022-07-21 Washington University MHC-INDEPENDENT TCRs AND METHODS OF MAKING AND USING SAME
KR20240038028A (ko) * 2021-07-27 2024-03-22 이매틱스 바이오테크놀로지스 게엠베하 Ct45에 특이적으로 결합하는 항원 결합 단백질

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69031914T2 (de) * 1989-08-11 1998-07-30 Amrad Corp. Ltd., Kew, Victoria Rezeptor für granulozyten-macrophagen-koloniestimulierungsfaktor und seine derivate
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
WO2002048370A2 (en) 2000-10-31 2002-06-20 Diadexus, Inc. Compositions and methods relating to colon specific genes and proteins
PL1999152T3 (pl) * 2006-03-27 2013-05-31 Medimmune Ltd Element wiążący receptor GM-CSF
US20090304657A1 (en) * 2006-05-03 2009-12-10 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Chimeric t cell receptors and related materials and methods of use
US8088379B2 (en) * 2006-09-26 2012-01-03 The United States Of America As Represented By The Department Of Health And Human Services Modified T cell receptors and related materials and methods
AU2007314164B2 (en) * 2006-11-03 2013-05-02 Central Adelaide Local Health Network Inc Operating As Sa Pathology Crystalline composition of GM-CSF/GM-CSFR
US8785601B2 (en) 2009-01-28 2014-07-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors and related materials and methods of use
WO2011029126A1 (en) * 2009-09-14 2011-03-17 Walter And Eliza Hall Institute Of Medical Research Methods and reagents for producing antibodies against autoantigens
EP3213765B1 (en) * 2010-09-20 2019-08-28 BioNTech Cell & Gene Therapies GmbH Antigen-specific t cell receptors and t cell epitopes

Also Published As

Publication number Publication date
US20150313978A1 (en) 2015-11-05
HUE042967T2 (hu) 2019-07-29
CA2894966C (en) 2021-03-30
PT2932264T (pt) 2019-05-21
ES2721159T3 (es) 2019-07-29
SI2932264T1 (sl) 2019-05-31
EP2932264B1 (en) 2019-01-30
WO2014091034A1 (en) 2014-06-19
TR201905447T4 (tr) 2019-05-21
CA3108192A1 (en) 2014-06-19
JP6475166B2 (ja) 2019-02-27
US9861688B2 (en) 2018-01-09
AU2013357239A1 (en) 2015-06-18
PL2932264T3 (pl) 2019-09-30
US20180099033A1 (en) 2018-04-12
AU2013357239B2 (en) 2019-10-17
EP2932264A1 (en) 2015-10-21
AU2019236675A1 (en) 2019-10-17
CA2894966A1 (en) 2014-06-19
US10987413B2 (en) 2021-04-27
JP2016501268A (ja) 2016-01-18
AU2019236675B2 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
FR23C1020I2 (fr) Conjugues pyrrolobenzodiazepine-anticorps
DK2934584T3 (da) Anti-gdf15-antistoffer
DK2850101T3 (da) Anti-FcRn-antistoffer
DK3117837T3 (da) Antistofformuleringer
DK2858671T3 (da) Antistofformulering
DK3049441T3 (da) Anti-PDL1-antistofformuleringer
DK2890397T3 (da) Antiprolactinreceptor-antistofformulering
DK3275892T3 (da) Præfusions-rsv-f-antigener
CO6801776A2 (es) Cosmético
DK2906251T3 (da) Pyrrolobenzodiazepin-anti-CD22-antistofkonjugater
DK2858676T3 (da) Prostata-specifikke membran-antigen-antistof-lægemiddelkonjugater
BR112015008232A2 (pt) conjugados pirrolbenzodiazepina-anticorpo
DK2825087T3 (da) Otoscanner
DK2864426T3 (da) Justerbare materialer
BR112014024373A2 (pt) anticorpos regulados por protease
CO6990736A2 (es) Pirrolidina-2-carboxamidas sustituídas
DE112012006109A5 (de) Okklusionsschienenanordnung
BR112014025037A2 (pt) anticorpo ou um fragmento funcional do mesmo, nucleotídeo, vetor recombinante, célula, métodos para a produção de um anticorpo ou fragmento funcional, para detecção ou ensaio de fgfr2 humano iiib, para a identificação de um indivíduo receptor de uma composição farmacêutica, e, para identificar e para produzir uma substância, forma modificada, composição, e, reagente
DK2825157T3 (da) Aminosyrelipider
DK2839284T3 (da) Mikropartikelanordning
DK2828292T3 (da) Jcv-neutraliserende antistoffer
DK2917244T3 (da) Aprotinin-afledte polypeptid-antistofkonjugater
DK2934582T3 (da) Anti-her2-antistofformulering
DK3431504T3 (da) Antiphospholipase d4-antistof
DK2932264T3 (da) Nye MHC-uafhængige tumor-associerede antigener